{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03568656",
            "orgStudyIdInfo": {
                "id": "CCS1477-01"
            },
            "organization": {
                "fullName": "CellCentric Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate CCS1477 in Advanced Tumours",
            "officialTitle": "An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-to-evaluate-in-advanced-tumours"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-07-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-06-04",
            "studyFirstSubmitQcDate": "2018-06-14",
            "studyFirstPostDateStruct": {
                "date": "2018-06-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "CellCentric Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Castration-Resistant Prostate Cancer",
                "Metastatic Breast Cancer",
                "Non-small Cell Lung Cancer",
                "Advanced Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The RP2D/MTD dose will be determined in Part A. Parts B-H will run in parallel after the completion of Part A.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 350,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "CCS1477 dose escalation - mCRPC",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 monotherapy in patients with mCRPC",
                    "interventionNames": [
                        "Drug: CCS1477"
                    ]
                },
                {
                    "label": "CCS1477 expansion phase - mCRPC",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 monotherapy in patients with mCRPC",
                    "interventionNames": [
                        "Drug: CCS1477"
                    ]
                },
                {
                    "label": "CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 plus abiraterone acetate in patients with mCRPC",
                    "interventionNames": [
                        "Drug: CCS1477",
                        "Drug: Abiraterone acetate"
                    ]
                },
                {
                    "label": "CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 plus enzalutamide in patients with mCRPC",
                    "interventionNames": [
                        "Drug: CCS1477",
                        "Drug: Enzalutamide"
                    ]
                },
                {
                    "label": "CCS1477 Monotherapy - Solid tumours",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 expansion phase in patients with advanced solid tumours with molecular markers which may indicate potential for response to p300/CBP inhibition",
                    "interventionNames": [
                        "Drug: CCS1477"
                    ]
                },
                {
                    "label": "CCS1477 and darolutamide, combination dose finding and expansion - mCRPC",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 plus darolutamide in patients with mCRPC",
                    "interventionNames": [
                        "Drug: CCS1477",
                        "Drug: Darolutamide"
                    ]
                },
                {
                    "label": "CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 plus olaparib in patients with mCRPC or metastatic breast cancer.",
                    "interventionNames": [
                        "Drug: CCS1477",
                        "Drug: Olaparib"
                    ]
                },
                {
                    "label": "CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer",
                    "type": "EXPERIMENTAL",
                    "description": "CCS1477 plus atezolizumab in patients with non-small cell lung cancer",
                    "interventionNames": [
                        "Drug: CCS1477",
                        "Drug: Atezolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "CCS1477",
                    "description": "Capsules, oral",
                    "armGroupLabels": [
                        "CCS1477 Monotherapy - Solid tumours",
                        "CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC",
                        "CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer",
                        "CCS1477 and darolutamide, combination dose finding and expansion - mCRPC",
                        "CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC",
                        "CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer",
                        "CCS1477 dose escalation - mCRPC",
                        "CCS1477 expansion phase - mCRPC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abiraterone acetate",
                    "description": "Abiraterone acetate 500mg tablets plus prednisone/prednisolone",
                    "armGroupLabels": [
                        "CCS1477 and abiraterone acetate, combination dose finding and expansion - mCRPC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Enzalutamide",
                    "description": "Enzalutamide 40mg capsules/tablets",
                    "armGroupLabels": [
                        "CCS1477 and enzalutamide, combination dose finding and expansion - mCRPC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Darolutamide",
                    "description": "300mg tablets",
                    "armGroupLabels": [
                        "CCS1477 and darolutamide, combination dose finding and expansion - mCRPC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olaparib",
                    "description": "150mg tablets",
                    "armGroupLabels": [
                        "CCS1477 and olaparib, combination dose finding and expansion - mCRPC and metastatic breast cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Atezolizumab",
                    "description": "840mg/14ml concentrate for solution for infusion vials",
                    "armGroupLabels": [
                        "CCS1477 and atezolizumab, combination dose finding and expansion - non-small cell lung cancer"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of treatment-related adverse events",
                    "description": "Treatment-related adverse events and serious adverse events",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Laboratory assessments",
                    "description": "Clinical chemistry and haematology assessments",
                    "timeFrame": "Up to 12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PSA response",
                    "description": "PSA response as defined by Prostate Cancer Clinical Trial Working Group 3 (PCWG-3)",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CTC response",
                    "description": "CTC response defined as a change from unfavourable (five or more cells) at baseline to favourable (four or fewer cells) post treatment",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Objective response rate (ORR)",
                    "description": "* malignant soft tissue response rate (Response Evaluation Criteria in Solid Tumours \\[RECIST\\] v1.1)\n* metastatic bone disease status (PCWG-3 bone scan criteria)",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "Radiological progression-free survival (rPFS)",
                    "description": "Defined as the time from start of treatment until objective disease progression as defined by RECIST 1.1 or PCWG-3 or death",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "AUC of CCS1477",
                    "description": "Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477",
                    "timeFrame": "Up to 30 days after first dose of CCS1477"
                },
                {
                    "measure": "Cmax of CCS1477",
                    "description": "Maximum observed plasma concentration (Cmax) of CCS1477",
                    "timeFrame": "Up to 30 days after first dose of CCS1477"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of consent\n* ECOG performance status 0-1\n* Assessable disease (by CT, MRI, bone scan or X-ray)\n* Adequate organ function\n* Highly effective contraception measures for duration of study\n\nAdditional inclusion criteria for mCRPC patients only:\n\n* Previously received abiraterone and/or enzalutamide (or equivalent anti-androgen), and docetaxel (unless ineligible or refused)\n* Progressive disease documented by one or more of the following:\n\n  * Biochemical progression defined as at least 2 stepwise increases in a series of any 3 PSA values\n  * Progression as defined by RECIST v1.1 guideline for assessment of malignant soft tissue disease.\n  * Progression defined as two or more new metastatic bone lesions confirmed on bone scan from a previous assessment\n* PSA at screening \u22652 \u03bcg/L\n* Serum testosterone concentration \u226450 ng/dL\n* Serum albumin \\>2.5 g/dL\n\nAdditional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:\n\n* Patients must have previously progressed on abiraterone treatment\n* Patients whose last dose of abiraterone is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with abiraterone to confirm refractoriness to abiraterone treatment\n\nAdditional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:\n\n* Patients must have previously progressed on enzalutamide treatment\n* Patients whose last dose of enzalutamide is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with enzalutamide to confirm refractoriness to enzalutamide treatment\n\nAdditional inclusion criteria for patients in mutation arm:\n\n* Advanced solid tumour with identification of markers which may indicate potential for response to p300/CBP inhibition. Markers include loss of function mutations in CREBBP, EP300 or ARID1A, MYC gene amplifications or rearrangements and androgen receptor (AR) gene amplifications or over-expression.\n\nExclusion Criteria:\n\n* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose\n* Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks of the first dose of study treatment\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment\n* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment\n* Statins\u037e patients should discontinue statins prior to starting study treatment\n* Any unresolved reversible toxicities from prior therapy \\>CTCAE grade 1 at the time of starting study treatment\n* Any evidence of severe or uncontrolled systemic diseases\n* Any known uncontrolled inter-current illness\n* QTcF prolongation (\\> 480 msec).\n* Primary brain tumours or known or suspected brain metastases.\n\nAdditional exclusion criteria for patients in CCS1477 plus abiraterone combination arm:\n\n* Clinically significant cardiac abnormalities\n\nAdditional exclusion criteria for patients in CCS1477 plus enzalutamide combination arm:\n\n* History of seizures or other predisposing factors\n* Use of substrates with a narrow therapeutic index metabolised by CYP2C9 or CYP2C19 within 2 weeks of the first dose of study treatment\n* Clinically significant cardiac abnormalities",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Tomasz Knurowski, MD, MFPM",
                    "role": "CONTACT",
                    "phone": "07882 871299",
                    "email": "Tomasz.Knurowski@cellcentric.com"
                },
                {
                    "name": "Karen Clegg, PhD",
                    "role": "CONTACT",
                    "email": "Karen.Clegg@cellcentric.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Johann de Bono, MD",
                    "affiliation": "Royal Marsden NHS Foundation Trust",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "COMPLETED",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "New York-Presbyterian Hospital/Weill Cornell Medical Center",
                    "status": "WITHDRAWN",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Thomas Jefferson University, Sidney Kimmel Cancer Center",
                    "status": "COMPLETED",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Institute Bergonie",
                    "status": "COMPLETED",
                    "city": "Bordeaux",
                    "zip": "33000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 44.84044,
                        "lon": -0.5805
                    }
                },
                {
                    "facility": "H\u00f4pital Europeen Georges Pompidou",
                    "status": "COMPLETED",
                    "city": "Paris",
                    "zip": "75015",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Institute Gustave Roussy",
                    "status": "COMPLETED",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Netherlands Cancer Institute (NKI)",
                    "status": "COMPLETED",
                    "city": "Amsterdam",
                    "zip": "1066 CX",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Erasmus MC Institute",
                    "status": "WITHDRAWN",
                    "city": "Rotterdam",
                    "zip": "3015 GD",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "Hospital Vall d'Hebron, VHIO",
                    "status": "COMPLETED",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "START CIOCC Hospital Universitario HM",
                    "status": "COMPLETED",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "INCLIVA Biomedical Research Institute",
                    "status": "WITHDRAWN",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                },
                {
                    "facility": "Karolinska Institute",
                    "status": "COMPLETED",
                    "city": "Stockholm",
                    "zip": "171 76",
                    "country": "Sweden",
                    "geoPoint": {
                        "lat": 59.33258,
                        "lon": 18.0649
                    }
                },
                {
                    "facility": "Belfast City Hospital",
                    "status": "RECRUITING",
                    "city": "Belfast",
                    "zip": "BT9 7AB",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Victoria Coyle",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.59682,
                        "lon": -5.92541
                    }
                },
                {
                    "facility": "Queen Elizabeth Hospital Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "zip": "B15 2TH",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Daniel Ford",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.48142,
                        "lon": -1.89983
                    }
                },
                {
                    "facility": "Cambridge University Hospital",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "zip": "CB2 0QQ",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Simon Pacey",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.2,
                        "lon": 0.11667
                    }
                },
                {
                    "facility": "Edinburgh Cancer Centre Western General Hospital",
                    "status": "RECRUITING",
                    "city": "Edinburgh",
                    "zip": "EH4 2XU",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Aravind Sundaramurthy",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 55.95206,
                        "lon": -3.19648
                    }
                },
                {
                    "facility": "The Beatson West of Scotland Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Glasgow",
                    "zip": "G12 0YN",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Richard Wilson",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 55.86515,
                        "lon": -4.25763
                    }
                },
                {
                    "facility": "Leicester Royal Infirmary",
                    "status": "RECRUITING",
                    "city": "Leicester",
                    "zip": "LE1 5WW",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Harriet Walter",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.6386,
                        "lon": -1.13169
                    }
                },
                {
                    "facility": "The Christie Hospital",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Louise Carter",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "Freeman Hospital",
                    "status": "RECRUITING",
                    "city": "Newcastle",
                    "zip": "NE7 7DN",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Ruth Plummer",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.97328,
                        "lon": -1.61396
                    }
                },
                {
                    "facility": "University Hospital Southampton",
                    "status": "RECRUITING",
                    "city": "Southampton",
                    "zip": "SO16 6YD",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Simon Crabb",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.90395,
                        "lon": -1.40428
                    }
                },
                {
                    "facility": "Royal Marsden Hospital",
                    "status": "RECRUITING",
                    "city": "Sutton",
                    "zip": "SM2 5NG",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Johann de Bono",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.35,
                        "lon": -0.2
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "36125208",
                    "type": "DERIVED",
                    "citation": "Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000594389",
                    "term": "Atezolizumab"
                },
                {
                    "id": "C000531550",
                    "term": "Olaparib"
                },
                {
                    "id": "D000069501",
                    "term": "Abiraterone Acetate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "relevance": "LOW"
                },
                {
                    "id": "M233003",
                    "name": "Olaparib",
                    "asFound": "Improvement",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11749",
                    "name": "Methylprednisolone",
                    "relevance": "LOW"
                },
                {
                    "id": "M1833",
                    "name": "Methylprednisolone Acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M11750",
                    "name": "Methylprednisolone Hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M14120",
                    "name": "Prednisolone",
                    "relevance": "LOW"
                },
                {
                    "id": "M229449",
                    "name": "Prednisolone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M211887",
                    "name": "Prednisolone hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248881",
                    "name": "Prednisolone phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M349417",
                    "name": "Atezolizumab",
                    "asFound": "Status",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "asFound": "Unilateral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "NeuroAg",
                    "name": "Neuroprotective Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}